4.8 Article

The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice

Journal

JOURNAL OF CLINICAL INVESTIGATION
Volume 122, Issue 4, Pages 1416-1426

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI60746

Keywords

-

Funding

  1. The Ministry of Education, Culture, Sports, Science, and Technology, Japan [22113009, 22113007, 22122003]
  2. Japan Society for the Promotion of Science
  3. Ministry of Health, Labour, and Welfare of Japan
  4. National Institute of Biomedical Innovation
  5. International Human Frontier Science Program
  6. Takeda Science Foundation
  7. Mitsubishi Foundation
  8. Japan Cardiovascular Research Foundation
  9. AstraZeneca
  10. Grants-in-Aid for Scientific Research [22116004, 22122003, 22116001, 22790891, 24659025, 22689030, 21390015, 23300152, 22113009, 22390040, 22113007] Funding Source: KAKEN

Ask authors/readers for more resources

The bioactive lysophospholipid mediator sphingosine-l-phosphate (SIP) promotes the egress of newly formed T cells from the thymus and the release of immature B cells from the bone marrow. It has remained unclear, however, where and how SIP is released. Here, we show that in mice, the SIP transporter spinster homolog 2 (Spns2) is responsible for the egress of mature T cells and immature B cells from the thymus and bone marrow, respectively. Global Spns2-KO mice exhibited marked accumulation of mature T cells in thymi and decreased numbers of peripheral T cells in blood and secondary lymphoid organs. Mature recirculating B cells were reduced in frequency in the bone marrow as well as in blood and secondary lymphoid organs. Bone marrow reconstitution studies revealed that Spns2 was not involved in SW release from blood cells and suggested a role for Spns2 in other cells. Consistent with these data, endothelia-specific deletion of Spns2 resulted in defects of lymphocyte egress similar to those observed in the global Spns2-KO mice. These data suggest that Spns2 functions in ECs to establish the S1P gradient required for T and B cells to egress from their respective primary lymphoid organs. Furthermore, Spns2 could be a therapeutic target for a broad array of inflammatory and autoimmune diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available